Structure and clinical relevance of the epidermal growth factor receptor in human cancer

Journal of Clinical Oncology

Volumn 26, Issue 10, 2008, Pages 1742-1751

  Kumar, Amit ^a   Petri, Edward T ^a   Halmos, Balazs ^a   Boggon, Titus J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; LAPATINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

CLINICAL EVALUATION; CRYSTAL STRUCTURE; DRUG EFFICACY; GENE ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM; PROTEIN QUATERNARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; HUMANS; MUTATION; NEOPLASMS; PROTEIN STRUCTURE, QUATERNARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 43249096031     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.1178     Document Type: Review

References (76)

1. Schlessinger J: Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306:1506-1507, 2004
2. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001
3. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
4. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
5. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
6. Stephens P, Hunter C, Bignell G, et al: Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526, 2004
7. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 411:355-365, 2001
8. Shigematsu H, Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257-262, 2006
9. Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319:1-11, 2004
10. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
11. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
12. Bailey R, Kris M, Wolf M, et al: Gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: Tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Cancer 41:S71, 2003
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
14. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005
15. Huang SF, Liu HP, Li LH, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-8203, 2004
16. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64:8919-8923, 2004
17. Politi K, Zakowski MF, Fan PD, et al: Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20:1496-1510, 2006
18. Ji H, Li D, Chen L, et al: The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9:485-495, 2006
19. Sordella R, Bell DW, Haber DA, et al: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-1167, 2004
20. Riely GJ, Pao W, Pham D, et al: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839-844, 2006
21. Jackman DM, Yeap BY, Sequist LV, et al: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12:3908-3914, 2006
22. Riely GJ, Politi KA, Miller VA, et al: Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12:7232-7241, 2006
23. Jänne PA, Engelman JA, Johnson BE: Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 23:3227-3234, 2005
24. Asahina H, Yamazaki K, Kinoshita I, et al: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95:998-1004, 2006
25. Inoue A, Suzuki T, Fukuhara T, et al: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24:3340-3346, 2006
26. Sutani A, Nagai Y, Udagawa K, et al: Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95:1483-1489, 2006
27. Hirsch FR, Witta S: Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 17:118-122, 2005
28. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005
29. Greulich H, Chen TH, Feng W, et al: Oncogenic transformation by inhibitor-sensitive and- resistant EGFR mutants. PLoS Med 2:e313, 2005
30. Jiang J, Greulich H, Janne PA, et al: Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65:8968-8974, 2005
31. Thomas RK, Greulich H, Yuza Y, et al: Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol 70:73-81, 2005
32. Choong NW, Dietrich S, Seiwert TY, et al: Gefitinib response of erlotinib-refractory lung cancer involving meninges: Role of EGFR mutation. Nat Clin Pract Oncol 3:50-57, 2006
33. Jones TA, Zhou JY, Cowan SW, et al: Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47:110-119, 1991
34. Stamos J, Sliwkowski MX, Eigenbrot C: Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277: 46265-46272, 2002
35. Wood ER, Truesdale AT, McDonald OB, et al: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:6652-6659, 2004
36. Zhang X, Gureasko J, Shen K, et al: An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149, 2006
37. Yun CH, Boggon TJ, Li Y, et al: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227, 2007
38. Huse M, Kuriyan J: The conformational plasticity of protein kinases. Cell 109:275-282, 2002
39. Nolen B, Taylor S, Ghosh G: Regulation of protein kinases; Controlling activity through activation segment conformation. Mol Cell 15:661-675, 2004
40. Tice DA, Biscardi JS, Nickles AL, et al: Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci U S A 96:1415-1420, 1999
41. Harrison SC: Variation on an Src-like theme. Cell 112:737-740, 2003
42. Xu W, Doshi A, Lei M, et al: Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3:629-638, 1999
43. Russo AA, Tong L, Lee JO, et al: Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395:237-243, 1998
44. Russo AA, Jeffrey PD, Patten AK, et al: Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382:325-331, 1996
45. Ross HJ, Blumenschein GR, Dowlati A, et al: Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 23:645s, 2005 (abstr 7099)
46. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER-2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
47. Konecny GE, Pegram MD, Venkatesan N, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639, 2006
48. Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002
49. O'Hare T, Corbin AS, Druker BJ: Targeted CML therapy: Controlling drug resistance, seeking cure. Curr Opin Genet Dev 16:92-99, 2006
50. Graham SM, Jorgensen HG, Allan E, et al: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319-325, 2002
51. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005
52. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
53. Balak MN, Gong Y, Riely GJ, et al: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494-6501, 2006
54. Branford S, Rudzki Z, Walsh S, et al: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472-3475, 2002
55. Tamborini E, Bonadiman L, Greco A, et al: A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127:294-299, 2004
56. Clark J, Cools J, Gilliland DG: EGFR inhibition in non-small cell lung cancer: Resistance, once again, rears its ugly head. PLoS Med 2:e75, 2005
57. Yun CH, Mengwasser KE, Toms AV, et al: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105:2070-2075, 2008
58. Sharma SV, Bell DW, Settleman J, et al: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181, 2007
59. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007
60. Yu Z, Jin C, Kobayashi S, et al: Predictive model of resistance mechanisms against irreversible EGFR inhibitors reveals novel treatment strategies. Cancer Res 67:10417-10427, 2007
61. Costa DB, Kobayashi S, Halmos B, et al: Bim mediates EGFR tyrosine kinase inhibitor induced apoptosis in non-small cell lung cancers and is linked to the resistance conferred by secondary EGFR mutations, T790M and the novel L747S. PLOS Med 4:1669-1680, 2007
62. Mendrola JM, Berger MB, King MC, et al: The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem 277: 4704-4712, 2002
63. Weisberg E, Manley PW, Cowan-Jacob SW, et al: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345-356, 2007
64. Garnett MJ, Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313-319, 2004
65. King AJ, Patrick DR, Batorsky RS, et al: Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 66:11100-11105, 2006
66. Burley SK: Cancer and kinases: Reports from the front line. Genome Biol 7:314, 2006
67. Weir B, Zhao X, Meyerson M: Somatic alterations in the human cancer genome. Cancer Cell 6:433-438, 2004
68. Engelman JA, Mukohara T, Zejnullahu K, et al: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116:2695-2706, 2006
69. Thomas RK, Nickerson E, Simons JF, et al: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12:852-855, 2006
70. Hubbard SR: EGF receptor inhibition: Attacks on multiple fronts. Cancer Cell 7:287-288, 2005
71. De Bondt HL, Rosenblatt J, Jancarik J, et al: Crystal structure of cyclin-dependent kinase 2. Nature 363:595-602, 1993
72. Jeffrey PD, Russo AA, Polyak K, et al: Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376: 313-320, 1995
73. CCP4: The CCP4 suite: Programs for protein crystallography. Acta Cryst D50:760-776, 1994
74. Hubbard SR, Wei L, Ellis L, et al: Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372:746-754, 1994
75. Blair JA, Rauh D, Kung C, et al: Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol 3:229-238, 2007
76. Zhang X, Pickin KA, Bose R, et al: Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450: 741-744, 2007